Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report

Hematological Oncology

Volumn 35, Issue 4, 2017, Pages 875-877

  Tardy, Magalie P ^a   Gastaud, Lauris ^a   Boscagli, Annick ^a   Peyrade, Frederic ^a   Gallamini, Andrea ^a   Thyss, Antoine ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

autoimmune hemolytic anemia; Hodgkin disease; immunotherapy; nivolumab; side effects

Indexed keywords

BENDAMUSTINE; BILIRUBIN; BLEOMYCIN; BRENTUXIMAB VEDOTIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN G ANTIBODY; LACTATE DEHYDROGENASE; NIVOLUMAB; PREDNISONE; VINBLASTINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

AGED; ANOREXIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD CHEMISTRY; CASE REPORT; CLINICAL ARTICLE; CONFORMAL RADIOTHERAPY; COOMBS TEST; CORTICOSTEROID THERAPY; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HODGKIN DISEASE; HUMAN; HYPERMETABOLISM; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; RETICULOCYTE; COMPLICATION;

AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84994613864     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2338     Document Type: Article

References (9)

1. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
2. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(18):2092–22099.
3. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3067.
4. Siddiqui N, Aleem A. Autoimmune haemolytic anaemia preceding the diagnosis of Hodgkin's disease: a report of two cases and review of the literature. JPMA J Pak Med Assoc. 2009;59(5):316–319.
5. Salmeron G, Molina TJ, Fieschi C, Zagdanski A-M, Brice P, Sibon D. Autoimmune hemolytic anemia and nodular lymphocyte-predominant hodgkin lymphoma: a rare association. Case Rep Hematol. 2013;2013:567289.
6. Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24(4-5):143–150.
7. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
8. Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 2016;19.
9. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica. 2013;2013:857519.